Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Stem Neoplasms | 1 | 2017 | 6 | 0.590 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2016 | 6 | 0.590 |
Why?
|
Pons | 1 | 2017 | 35 | 0.590 |
Why?
|
Glioma | 1 | 2017 | 140 | 0.540 |
Why?
|
Meningioma | 3 | 2020 | 54 | 0.520 |
Why?
|
Seizures | 1 | 2016 | 279 | 0.490 |
Why?
|
Pediatrics | 1 | 2017 | 341 | 0.460 |
Why?
|
Glioblastoma | 3 | 2020 | 219 | 0.440 |
Why?
|
Brain Neoplasms | 3 | 2020 | 371 | 0.400 |
Why?
|
Tumor Suppressor Proteins | 3 | 2020 | 194 | 0.380 |
Why?
|
Meningeal Neoplasms | 2 | 2020 | 42 | 0.350 |
Why?
|
Basilar Artery | 2 | 2016 | 38 | 0.280 |
Why?
|
Arterial Occlusive Diseases | 2 | 2016 | 134 | 0.260 |
Why?
|
DNA Modification Methylases | 2 | 2020 | 24 | 0.240 |
Why?
|
Cyclin-Dependent Kinase 6 | 2 | 2020 | 27 | 0.230 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2020 | 34 | 0.230 |
Why?
|
DNA Repair Enzymes | 2 | 2020 | 53 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 57 | 0.230 |
Why?
|
Thrombectomy | 2 | 2016 | 238 | 0.230 |
Why?
|
Benzimidazoles | 2 | 2020 | 128 | 0.220 |
Why?
|
Neurofibromin 2 | 1 | 2020 | 10 | 0.190 |
Why?
|
Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.190 |
Why?
|
Lanosterol | 1 | 2019 | 11 | 0.180 |
Why?
|
Heptanoic Acids | 1 | 2019 | 28 | 0.180 |
Why?
|
Quinolones | 1 | 2020 | 60 | 0.180 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2020 | 79 | 0.180 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 100 | 0.180 |
Why?
|
Triterpenes | 1 | 2019 | 40 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2020 | 222 | 0.170 |
Why?
|
Fasciitis | 1 | 2019 | 30 | 0.170 |
Why?
|
Craniocerebral Trauma | 1 | 2019 | 50 | 0.170 |
Why?
|
Head | 1 | 2019 | 59 | 0.170 |
Why?
|
Piperazines | 1 | 2020 | 206 | 0.160 |
Why?
|
Allyl Compounds | 1 | 2018 | 29 | 0.160 |
Why?
|
Sulfides | 1 | 2018 | 43 | 0.160 |
Why?
|
Pyridines | 1 | 2020 | 261 | 0.160 |
Why?
|
Histone Deacetylases | 1 | 2018 | 99 | 0.150 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 116 | 0.150 |
Why?
|
Biotinidase Deficiency | 1 | 2016 | 2 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 444 | 0.140 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 1849 | 0.130 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2016 | 134 | 0.120 |
Why?
|
Electroencephalography | 1 | 2016 | 418 | 0.120 |
Why?
|
Stroke | 2 | 2016 | 2161 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 1070 | 0.110 |
Why?
|
Humans | 11 | 2020 | 68525 | 0.100 |
Why?
|
Brain Ischemia | 1 | 2016 | 665 | 0.090 |
Why?
|
Infant | 1 | 2017 | 2891 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 2 | 2020 | 111 | 0.090 |
Why?
|
Child, Preschool | 1 | 2016 | 3185 | 0.090 |
Why?
|
Mice, SCID | 2 | 2019 | 238 | 0.080 |
Why?
|
Apoptosis | 3 | 2020 | 1640 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2020 | 331 | 0.080 |
Why?
|
Treatment Outcome | 2 | 2016 | 7028 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 2222 | 0.080 |
Why?
|
Astrocytes | 2 | 2020 | 270 | 0.070 |
Why?
|
Female | 3 | 2019 | 38015 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 951 | 0.070 |
Why?
|
Cell Proliferation | 2 | 2020 | 1173 | 0.070 |
Why?
|
Male | 5 | 2020 | 37281 | 0.070 |
Why?
|
Neurons | 2 | 2020 | 881 | 0.060 |
Why?
|
G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 12 | 0.050 |
Why?
|
Cyclin D | 1 | 2020 | 12 | 0.050 |
Why?
|
Smad Proteins | 1 | 2020 | 25 | 0.050 |
Why?
|
Guanine | 1 | 2020 | 21 | 0.050 |
Why?
|
Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
Aminopyridines | 1 | 2020 | 26 | 0.050 |
Why?
|
bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
Quinolines | 1 | 2020 | 48 | 0.050 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 71 | 0.050 |
Why?
|
Triazines | 1 | 2020 | 48 | 0.050 |
Why?
|
Wnt2 Protein | 1 | 2019 | 4 | 0.050 |
Why?
|
Anaplasia | 1 | 2019 | 7 | 0.050 |
Why?
|
Azacitidine | 1 | 2019 | 20 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2020 | 75 | 0.050 |
Why?
|
Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2019 | 110 | 0.040 |
Why?
|
Caspase 3 | 1 | 2020 | 233 | 0.040 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 77 | 0.040 |
Why?
|
Benzamides | 1 | 2020 | 156 | 0.040 |
Why?
|
Fascia | 1 | 2019 | 17 | 0.040 |
Why?
|
Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
Cell Cycle | 1 | 2020 | 312 | 0.040 |
Why?
|
Skull | 1 | 2019 | 63 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2019 | 160 | 0.040 |
Why?
|
Cell Death | 1 | 2019 | 329 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
In Vitro Techniques | 1 | 2019 | 765 | 0.040 |
Why?
|
DNA Methylation | 1 | 2019 | 192 | 0.040 |
Why?
|
Down-Regulation | 1 | 2019 | 447 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2020 | 799 | 0.040 |
Why?
|
Mice | 2 | 2020 | 8472 | 0.040 |
Why?
|
Animals | 3 | 2020 | 20877 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 614 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 331 | 0.040 |
Why?
|
Cell Survival | 1 | 2020 | 901 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 467 | 0.040 |
Why?
|
Phosphorylation | 1 | 2019 | 1199 | 0.040 |
Why?
|
Verapamil | 1 | 2016 | 30 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 756 | 0.030 |
Why?
|
Cerebral Angiography | 1 | 2016 | 151 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 1139 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2016 | 138 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2020 | 2673 | 0.030 |
Why?
|
Child | 2 | 2016 | 6400 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
Endovascular Procedures | 1 | 2016 | 366 | 0.030 |
Why?
|
Signal Transduction | 1 | 2020 | 2688 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 2323 | 0.020 |
Why?
|
Adolescent | 1 | 2019 | 8903 | 0.020 |
Why?
|
Aged | 1 | 2019 | 14842 | 0.010 |
Why?
|
Middle Aged | 1 | 2019 | 21119 | 0.010 |
Why?
|